• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲“非酒精性脂肪性肝病准备指数”——欧洲是否做好应对脂肪肝疾病挑战的准备?

European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?

作者信息

Lazarus Jeffrey V, Palayew Adam, Carrieri Patrizia, Ekstedt Mattias, Marchesini Giulio, Novak Katja, Ratziu Vlad, Romero-Gómez Manuel, Tacke Frank, Zelber-Sagi Shira, Cortez-Pinto Helena, Anstee Quentin M

机构信息

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.

McGill University Department of Epidemiology, Biostatistics, and Occupational Health, Montreal, Canada.

出版信息

JHEP Rep. 2021 Jan 21;3(2):100234. doi: 10.1016/j.jhepr.2021.100234. eCollection 2021 Apr.

DOI:10.1016/j.jhepr.2021.100234
PMID:33733078
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7937562/
Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent emerging condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to ensure that health systems can deliver effective care. We present a NAFLD Preparedness Index for Europe.

METHODS

In June 2019, data were extracted by expert groups from 29 countries to complete a 41-item questionnaire about NAFLD. Questions were classified into 4 categories: policies/civil society (9 questions), guidelines (16 questions), epidemiology (4 questions), and care management (12 questions). Based on the responses, national preparedness for each indicator was classified into low, middle, or high-levels. We then applied a multiple correspondence analysis to obtain a standardised preparedness score for each country ranging from 0 to 100.

RESULTS

The analysis estimated a summary factor that explained 71.3% of the variation in the dataset. No countries were found to have yet attained a high-level of preparedness. Currently, the UK (75.5) scored best, although falling within the mid-level preparedness band, followed by Spain (56.2), and Denmark (43.4), whereas Luxembourg and Ireland were the lowest scoring countries with a score of 4.9. Only Spain scored highly in the epidemiology indicator category, whereas the UK was the only country that scored highly for care management.

CONCLUSIONS

The NAFLD Preparedness Index indicates substantial variation between countries' readiness to address NAFLD. Notably, even those countries that score relatively highly exhibit deficiencies in key domains, suggesting that structural changes are needed to optimise NAFLD management and ensure effective public health approaches are in place.

LAY SUMMARY

Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures aimed at preventing disease while also ensuring that health systems can deliver effective care to affected populations. This study defined preparedness as having adequate policies and civil society engagement, guidelines, epidemiology, and care management. NAFLD preparedness was found to be deficient in all 29 countries studied, with great variation among the countries and the 4 categories studied.

摘要

背景与目的

非酒精性脂肪性肝病(NAFLD)与肥胖、代谢综合征和糖尿病密切相关,是一种高度流行的新兴疾病,可通过以患者为中心的多学科方法进行最佳管理。国家应对NAFLD的准备工作对于确保卫生系统能够提供有效治疗至关重要。我们提出了一个欧洲NAFLD准备指数。

方法

2019年6月,专家组从29个国家提取数据,以完成一份关于NAFLD的41项问卷。问题分为4类:政策/民间社会(9个问题)、指南(16个问题)、流行病学(4个问题)和护理管理(12个问题)。根据回答,将每个指标的国家准备情况分为低、中、高三个级别。然后,我们应用多重对应分析来获得每个国家从0到100的标准化准备得分。

结果

分析估计了一个汇总因子,该因子解释了数据集中71.3%的变异。未发现有国家达到高级别的准备状态。目前,英国(75.5)得分最高,尽管仍处于中级准备范围,其次是西班牙(56.2)和丹麦(43.4),而卢森堡和爱尔兰是得分最低的国家,得分为4.9。只有西班牙在流行病学指标类别中得分较高,而英国是唯一在护理管理方面得分较高的国家。

结论

NAFLD准备指数表明各国应对NAFLD的准备程度存在很大差异。值得注意的是,即使是那些得分相对较高的国家在关键领域也存在不足,这表明需要进行结构调整以优化NAFLD管理并确保有效的公共卫生方法到位。

简要概述

非酒精性脂肪性肝病(NAFLD)与肥胖、代谢综合征和糖尿病密切相关,是一种高度流行的疾病,可通过以患者为中心的多学科方法进行最佳管理。国家应对NAFLD的准备工作对于采取有效的公共卫生措施以预防疾病并确保卫生系统能够为受影响人群提供有效治疗至关重要。本研究将准备情况定义为具备适当的政策、民间社会参与、指南、流行病学和护理管理。研究发现,在所有29个研究国家中,NAFLD准备情况均存在不足,在所研究的国家和4个类别中差异很大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f935/7937562/b6f7e63bfbb4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f935/7937562/b0b9a4f38f25/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f935/7937562/b6f7e63bfbb4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f935/7937562/b0b9a4f38f25/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f935/7937562/b6f7e63bfbb4/gr1.jpg

相似文献

1
European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?欧洲“非酒精性脂肪性肝病准备指数”——欧洲是否做好应对脂肪肝疾病挑战的准备?
JHEP Rep. 2021 Jan 21;3(2):100234. doi: 10.1016/j.jhepr.2021.100234. eCollection 2021 Apr.
2
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?全球非酒精性脂肪性肝病政策审查与准备指数:各国是否准备好应对这一无声的公共卫生挑战?
J Hepatol. 2022 Apr;76(4):771-780. doi: 10.1016/j.jhep.2021.10.025. Epub 2021 Dec 9.
3
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.一项关于欧洲对非酒精性脂肪性肝病公共卫生应对措施的横断面研究。
J Hepatol. 2020 Jan;72(1):14-24. doi: 10.1016/j.jhep.2019.08.027. Epub 2019 Sep 10.
4
EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?EASL-EASD-EASO 临床实践指南:严重肥胖人群非酒精性脂肪性肝病的管理——是否导致过度转诊?
Diabetologia. 2017 Jul;60(7):1218-1222. doi: 10.1007/s00125-017-4264-9. Epub 2017 Mar 28.
5
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.欧洲和美国非酒精性脂肪性肝炎的成本:GAIN研究。
JHEP Rep. 2020 Jul 15;2(5):100142. doi: 10.1016/j.jhepr.2020.100142. eCollection 2020 Oct.
6
Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions.非酒精性脂肪性肝炎的实际管理与临床实践指南建议不同,且存在地区差异。
JHEP Rep. 2021 Nov 22;4(1):100411. doi: 10.1016/j.jhepr.2021.100411. eCollection 2022 Jan.
7
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会非酒精性脂肪性肝病管理临床实践指南:普遍筛查是否合适?
Diabetologia. 2016 Jun;59(6):1141-4. doi: 10.1007/s00125-016-3910-y. Epub 2016 Apr 7.
8
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.全球 2 型糖尿病患者非酒精性脂肪性肝病和非酒精性脂肪性肝炎的流行病学:系统评价和荟萃分析。
J Hepatol. 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021. Epub 2019 Jul 4.
9
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.建立中国、法国、德国、意大利、日本、西班牙、英国和美国 2016-2030 年非酒精性脂肪性肝病疾病负担模型。
J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.
10
[Non-alcoholic fatty liver disease - a summary and update based on the EASL-EASD-EASO Clinical Practice Guidelines of 2016].[非酒精性脂肪性肝病——基于2016年欧洲肝脏研究学会(EASL)、欧洲糖尿病研究学会(EASD)和欧洲肥胖研究学会(EASO)临床实践指南的总结与更新]
Orv Hetil. 2018 Nov;159(45):1815-1830. doi: 10.1556/650.2018.31231.

引用本文的文献

1
Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective.代谢功能障碍相关脂肪性肝病(MASLD)的管理——来自印度糖尿病专家视角的专家共识声明
Diabetes Obes Metab. 2025 Jun;27 Suppl 4(Suppl 4):3-20. doi: 10.1111/dom.16496. Epub 2025 Jun 2.
2
Global research initiative for patient screening on MASH (GRIPonMASH) protocol: rationale and design of a prospective multicentre study.全球MASH患者筛查研究倡议(GRIPonMASH)方案:一项前瞻性多中心研究的基本原理与设计
BMJ Open. 2025 May 30;15(5):e092731. doi: 10.1136/bmjopen-2024-092731.
3

本文引用的文献

1
Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review.FIB-4、非酒精性脂肪性肝病纤维化评分和APRI对非酒精性脂肪性肝病相关事件的预后准确性:一项系统评价。
Liver Int. 2021 Feb;41(2):261-270. doi: 10.1111/liv.14669.
2
The socioeconomic aspects of nonalcoholic fatty liver disease: food insecurity as a novel risk factor for steatosis and liver fibrosis.非酒精性脂肪性肝病的社会经济层面:粮食不安全作为脂肪变性和肝纤维化的一种新风险因素
Hepatobiliary Surg Nutr. 2020 Aug;9(4):543-545. doi: 10.21037/hbsn.2020.03.03.
3
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
Current strategies for nonalcoholic fatty liver disease treatment (Review).
目前非酒精性脂肪性肝病治疗策略(综述)。
Int J Mol Med. 2024 Oct;54(4). doi: 10.3892/ijmm.2024.5412. Epub 2024 Aug 12.
4
Health-related quality of life in non-alcoholic fatty liver disease: A cross-cultural study between Spain and the United Kingdom.非酒精性脂肪性肝病患者的健康相关生活质量:西班牙和英国之间的跨文化研究。
PLoS One. 2024 May 6;19(5):e0300362. doi: 10.1371/journal.pone.0300362. eCollection 2024.
5
Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severity.代谢相关性脂肪性肝病患者的焦虑和抑郁:与社会人口学特征和肝病严重程度的关系。
Acta Diabetol. 2024 Aug;61(8):1041-1051. doi: 10.1007/s00592-024-02287-0. Epub 2024 Apr 29.
6
A Machine Learning Method to Identify the Risk Factors for Liver Fibrosis Progression in Nonalcoholic Steatohepatitis.一种机器学习方法,用于识别非酒精性脂肪性肝炎肝纤维化进展的危险因素。
Dig Dis Sci. 2023 Sep;68(9):3801-3809. doi: 10.1007/s10620-023-08031-y. Epub 2023 Jul 21.
7
Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD - An Umbrella Overview of Systematic Review of Meta-Analysis.非酒精性脂肪性肝病的肝脏、肝外结局及死亡原因——一项荟萃分析系统评价的伞状综述
J Clin Exp Hepatol. 2023 Jul-Aug;13(4):656-665. doi: 10.1016/j.jceh.2022.11.006. Epub 2022 Nov 19.
8
Gut Microbiota-A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review.肠道微生物群——非酒精性脂肪性肝病患者的未来治疗靶点:系统评价。
Int J Mol Sci. 2022 Jul 27;23(15):8307. doi: 10.3390/ijms23158307.
9
Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey.从肝病学家、胃肠病学家和患者的角度看非酒精性脂肪性肝炎患者的就医旅程:一项横断面调查。
BMC Gastroenterol. 2022 Jul 10;22(1):335. doi: 10.1186/s12876-022-02410-x.
10
Banting memorial lecture 2022: 'Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime'.2022 年班廷纪念讲座:“2 型糖尿病与非酒精性脂肪性肝病:罪恶的伙伴”。
Diabet Med. 2022 Oct;39(10):e14912. doi: 10.1111/dme.14912. Epub 2022 Jul 20.
欧洲和美国非酒精性脂肪性肝炎的成本:GAIN研究。
JHEP Rep. 2020 Jul 15;2(5):100142. doi: 10.1016/j.jhepr.2020.100142. eCollection 2020 Oct.
4
Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?负担最重的国家是否拥有消除乙型和丙型病毒性肝炎的正确政策?
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):948-953. doi: 10.1016/S2468-1253(20)30011-X. Epub 2020 Jul 27.
5
The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.Hep-CORE 政策评分:基于患者组织数据的欧洲丙型肝炎国家政策实施排名。
PLoS One. 2020 Jul 28;15(7):e0235715. doi: 10.1371/journal.pone.0235715. eCollection 2020.
6
Ultra-Processed Food Consumption among the Paediatric Population: An Overview and Call to Action from the European Childhood Obesity Group.儿科人群中超加工食品的消费:欧洲儿童肥胖问题小组的概述与行动呼吁
Ann Nutr Metab. 2020;76(2):109-113. doi: 10.1159/000507840. Epub 2020 Apr 28.
7
Therapeutic Landscape for NAFLD in 2020.2020 年非酒精性脂肪性肝病的治疗性景观。
Gastroenterology. 2020 May;158(7):1984-1998.e3. doi: 10.1053/j.gastro.2020.01.051. Epub 2020 Feb 13.
8
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD.2012 年至 2017 年全球慢性肝病负担的变化:非酒精性脂肪性肝病的影响日益增加。
Hepatology. 2020 Nov;72(5):1605-1616. doi: 10.1002/hep.31173. Epub 2020 Oct 27.
9
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.奥贝胆酸治疗非酒精性脂肪性肝炎:多中心、随机、安慰剂对照 3 期临床试验的中期分析。
Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5.
10
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.全球、区域和国家癌症发病率、死亡率、生命损失年数、失能生存年数以及 29 种癌症组别的伤残调整生命年数:1990 至 2017 年全球疾病负担研究的系统分析。
JAMA Oncol. 2019 Dec 1;5(12):1749-1768. doi: 10.1001/jamaoncol.2019.2996.